Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections. A drug's activity against MRSA is among the top factors that influences European physician drug selection for treating skin and skin structure infections. Other key factors that drive prescribing include an agent's skin penetration, its spectrum of activity and recommended use by national and hospital guidelines.

The new report entitled Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections (Europe) also finds that novel antibiotics in late-stage development may become useful therapeutic options for European physicians given their concern over MRSA. Two new injectable cephalosporins, Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca/Takeda's ceftaroline, offer broad-spectrum activity against MRSA and may provide convenient monotherapy options for physicians requiring broad-spectrum activity against gram-positive and gram-negative pathogens. Surveyed European specialists express willingness to use these agents in empiric therapy for complicated skin and skin structure infections, particularly in patients with suspected MRSA infections.

"Specialists we surveyed in Europe told us that they anticipate shifts in prescribing that will impact the skin structure infection market in the near future. In particular, physicians believe they will increase their empiric coverage of MRSA in complicated skin and skin structure infections," stated Decision Resources Analyst Lisa Arias. "MRSA infections are a great concern in the hospital setting and are a growing concern in the community setting because of their association with poorer outcomes and higher healthcare costs compared with non-resistant infections."

About the Report

AMR and Decision Resources' Hospital Anti-Infectives Insight Series: Skin and Skin Structure Infections (Europe) analyzes hospital antibiotic prescribing patterns in Europe using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. This report contains European data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:        Gisselle Morales                             Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563   gmorales@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources; Arlington Medical Resources

CONTACT: Gisselle Morales, Decision Resources, +1-781-296-2691,
gmorales@dresources.com, or Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018

View Now